About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Ocugen

< Previous 1 2 3 4 Next >
News headline image
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Provides Business Update with Third Quarter 2025 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Present at Industry and Investor Conferences in October 2025
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Provides Business Update with Second Quarter 2025 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases
From Ocugen
Via GlobeNewswire
Tickers CARM OCGN
News headline image
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen To Present at BIO International Convention 2025
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Provides Business Update with First Quarter 2025 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Present at the 2025 Cell & Gene Meeting on the Med
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease
From Ocugen
Via GlobeNewswire
Tickers OCGN
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.